0.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Allurion Technologies
From its filings with the US Securities and Exchange Commission
Allurion Technologies is based in Natick, Massachusetts and is incorporated in Delaware. Its shares trade on OTC under the ticker ALUR. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $15.2m and a net loss of $28.8m. At that date it held total assets of $15.8m and shareholders' equity of −$77.2m.
Our company is pioneering metabolically healthy weight loss by creating a best-in-class weight loss platform to treat the estimated two billion people globally who are overweight. Our platform, the Allurion Program (the "Allurion Program"), features the world’s first and only swallowable, ProcedurelessTM intragastric balloon for weight loss (the "Allurion Smart Capsule") and offers access to artificial intelligence ("AI")-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging and video telehealth that make up the Allurion Virtual Care Suite (“VCS”). Over 200,000 patients have already been treated commercially with the Allurion Smart Capsule in over 50 countries outside of the United States.
The Allurion Program was designed to achieve metabolically healthy weight loss, which entails losing weight, maintaining that weight loss, and maintaining or increasing muscle mass in the process. Unlike other options that lead to short-term weight loss and muscle wasting, the Allurion Program is intended to deliver longer lasting results while reducing fat and not muscle. We believe the Allurion Program is also synergistic in combination with other weight loss therapies, including glucagon-like peptide 1 ("GLP-1") receptor agonists.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Consumer Discretionary
- Industry
- Diversified Consumer Services
- Listed since
- 29 Mar 2021
- Employees
- 256
- Website
- allurion.com/en ↗
- Head office
- 11 HURON DR STE 200, NATICK, MA, 01760
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Omar IshrakChairman of the Board, since 2021
- Mr. Joshua FinkCo-Chief Executive Officer, Director, since 2021
- Dr. Jean NehmeCo-Chief Executive Officer, Director, since 2021
- Dr. Osama AlswailemIndependent Director
- Mr. Hani BarhoushIndependent Director
- Mr. Michael HarshIndependent Director
- Ms. Gwendolyn WatanabeIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Allurion Program offers a six-month weight loss platform combining gastric balloon and virtual care suite.
- Allurion Virtual Care Suite includes Iris AI Platform for health care providers and health tracker devices.
- Allurion Connected Scale provides comprehensive weight, BMI, and body composition tracking for users.
Weaknesses
- Allurion Health Tracker tracks steps, exercise, and sleep but lacks advanced health metrics.
- The company employs 256 full-time employees, which may limit scalability for rapid growth.
- Allurion Program is offered in six months, potentially limiting long-term engagement options.
Opportunities
- Expanding Allurion Virtual Care Suite to include more health metrics for providers.
- Increasing market penetration in the US Diversified Consumer Services sector.
- Integrating Allurion Health Tracker with additional wearable devices for broader appeal.
Threats
- Competition from other weight loss platforms in the Consumer Discretionary sector.
- Regulatory changes affecting health care provider services in the US.
- Potential market saturation in the weight loss industry segment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.